Literature DB >> 10806759

[Chemosensitivity test for 170 human breast carcinoma samples].

Z He1, J Yuan, Z Chen, S Liu, Z Shen, H Fei.   

Abstract

We tested the in vitro sensitivity of 170 primary breast carcinoma samples to the anti-cancer drugs conventionally used in clinical chemotherapy. It was found that: 1. The high sensitivity rate (HSR) of breast carcinoma cells to 5-fluorouracil (5-Fu), mitomycin (MMC), cisplatin (DDP), adriamycin(ADM), methotrexate(MTX), vincristin(VCR), vepesid(VP-16), taxol, and vindesine(VDS) were 57.1%, 49.4%, 48.3%, 35.8%, 21.8%, 21.2%, 10%, 18.2% and 20.9%, respectively. The increase of HSR of cancer cells to 5-Fu, MMC, DDP, taxol was more significant than that of the other drugs tested (P < 0.05). 2. No correlation was shown between drug sensitivity and factors, i.e. pathological type, clinical type, expression of estrogen receptor (ER) and epithelium growth factor receptor(EGFR) for breast carcinoma (P > 0.05). 3. Cyclosporin A can increase part of the sensitivity of ADM-resistant breast carcinoma cells to ADM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10806759

Source DB:  PubMed          Journal:  Hunan Yi Ke Da Xue Xue Bao        ISSN: 1000-5625


  3 in total

1.  Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis.

Authors:  Guopei Zheng; Fang Peng; Renkui Ding; Yanhui Yu; Yongmei Ouyang; Zhuchu Chen; Zhiqiang Xiao; Zhimin He
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-21       Impact factor: 4.553

2.  Inhibition of Mus81 by siRNA enhances sensitivity to 5-FU in breast carcinoma cell lines.

Authors:  Ying Qian; Yanning Liu; Qiuyue Yan; Juan Lv; Xiaoyan Ni; Yunlu Wu; Xuejun Dong
Journal:  Onco Targets Ther       Date:  2014-10-21       Impact factor: 4.147

3.  Expression of the breast cancer resistance protein and 5-fluorouracil resistance in clinical breast cancer tissue specimens.

Authors:  Min Wang; Xianming Wang; Jianhui Yuan; Liangfeng Guo
Journal:  Mol Clin Oncol       Date:  2013-07-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.